With AstraZeneca’s Crestor Launch In India, The Fight For Statins Market Is Set To Get Fiercer
This article was originally published in PharmAsia News
Executive Summary
MUMBAI -Two months after Merck brought Zocor (simvastatin) into India, its global rival AstraZeneca introduced Crestor (rosuvastatin) at one-fifth of its international prices. Crestor is used in the treatment of dyslipidemia and atherosclerosis
You may also be interested in...
Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years
MUMBAI - Buoyed by strong performance of its key brands Januvia (sitagliptin) and Gardasil launched last year in India, U.S. drug giant Merck is going full throttle in its ambition to figure in the top five companies in India by 2015
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).